Value | Change in ranking | |
Decrease in TST-positive contacts % | ≤26 | TST-based strategy less expensive than QFT-G-based strategy |
Reduction in cost of QFT-G EUR | ||
Base-case assumption | ≤27.20 | QFT-G-based strategy least expensive |
Lowest cost of RT 23# | ≤17.5 | QFT-G-based strategy least expensive |
Increase in BCG vaccinees % | ≥88 | TST/BCG/QFT-G-based strategy least expensive |
Decrease in BCG vaccinees % | ≤66 | QFT-G-based strategy less expensive than TST/BCG/QFT-G-based strategy |
Increase in cost of QFT-G EUR | ||
Base-case assumption | ≥73.8 | TST-based strategy less expensive than QFT-G-based strategy |
Lowest cost of RT 23# | ≥67.8 | TST-based strategy less expensive than QFT-G-based strategy |
TST: tuberculin skin test; QFT-G: QuantiFERON-TB Gold; EUR: Euro; RT 23: purified protein derivative of tuberculin RT 23 (2 TU·0.1 mL-1) from the Danish Statens Serum Institute; BCG: bacille Calmette–Guérin. #: 1.5 EUR·dose-1.